After identifying specific genetic mutations in the tumor, it is possible to tailor systemic therapy using drugs that target these mutations, such as BRAF, MEK, KIT inhibitors, or checkpoint inhibitors. The gene discussed is MAP2K7; the disease is neoplasm.